Filing Details
- Accession Number:
- 0001209191-21-024234
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-04-01 18:19:57
- Reporting Period:
- 2021-03-30
- Accepted Time:
- 2021-04-01 18:19:57
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1807120 | Design Therapeutics Inc. | DSGN | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1728741 | Stella Xu | C/O Design Therapeutics, Inc. 6005 Hidden Valley Road, Suite 110 Carlsbad CA 92011 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-03-30 | 4,439,839 | $0.00 | 4,439,839 | No | 4 | C | Indirect | See footnote |
| Common Stock | Acquisiton | 2021-03-30 | 280,991 | $0.00 | 4,720,830 | No | 4 | C | Indirect | See footnote |
| Common Stock | Acquisiton | 2021-03-30 | 10,000 | $20.00 | 4,730,830 | No | 4 | P | Indirect | By spouse |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | See footnote |
| No | 4 | C | Indirect | See footnote |
| No | 4 | P | Indirect | By spouse |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Preferred Stock | Disposition | 2021-03-30 | 7,236,938 | $0.00 | 4,439,839 | $0.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2021-03-30 | 458,016 | $0.00 | 280,991 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.
- The general partner of Quan Venture Fund II, L.P. is Quan Venture Partners II, L.L.C. Stella Xu is a managing director of Quan Venture Partners II, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Venture Fund II, L.P. Dr. Xu disclaims beneficial ownership of the shares held by Quan Venture Fund II, L.P., except to the extent of her pecuniary interest.
- The shares were purchased in the Issuer's initial public offering.
Billionaire Hedge Funds
